Coya Therapeutics, Inc. has announced a Securities Purchase Agreement of 603,136 shares at issue price of $8.29 per share for an aggregate gross proceeds of $4,999,997 on May 17, 2024. The transaction includes investor participation of new investor, Alzheimers Drug Discovery Foundation. The Shares issued to the ADDF under the Purchase Agreement were issued pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Rule 506 of Regulation D, which is promulgated under the Securities Act.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.485 USD | -4.07% | -19.84% | -12.48% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.48% | 98.71M | |
+34.01% | 51.07B | |
+33.84% | 38.86B | |
-8.02% | 38.78B | |
-8.98% | 26.69B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- COYA Stock
- News Coya Therapeutics, Inc.
- Coya Therapeutics, Inc. announced that it expects to receive $4.999997 million in funding from Alzheimers Drug Discovery Foundation